Asian Pacific Journal of Cancer Prevention

  • 제15권17호
  • /
  • Pages.7277-7280
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors

  • Zhang, Yong (Shiyan Taihe Hospital of Hubei Province Department of Pediatrics, The Affiliated Hospital of Hubei Medical College) ;
  • Sun, Ling-Li (Shiyan Taihe Hospital of Hubei Province Department of Pediatrics, The Affiliated Hospital of Hubei Medical College) ;
  • Li, Tao (Shiyan Taihe Hospital of Hubei Province Department of Pediatrics, The Affiliated Hospital of Hubei Medical College) ;
  • Sun, Hui (Shiyan Taihe Hospital of Hubei Province Department of Pediatrics, The Affiliated Hospital of Hubei Medical College) ;
  • Mao, Guo-Jia (Department of Surgery, Jiujiang Third People's Hospital of Jiangxi Province)
  • 발행 : 2014.09.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This analysis was conducted to evaluate the efficacy and safety of carboplatin based chemotherapy in treating pediatric patients with Wilms tumors. Methods: Clinical studies evaluating the efficacy and safety of carboplatin based regimens on response and safety for pediatric patients with Wilms tumors were identified using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated. Results: In carboplatin based regimens, 4 clinical studies which including 127 patients with advanced Wilms tumors were considered eligible for inclusion. With this carboplatin based chemotherapy, 2 clinical studies included carboplatin, ifosfamide and etoposide. Systemic analysis suggested that, in all patients, the pooled PR was 64.5% (82/127) in carboplatin based regimens. Thrombocytopenia and leukocytopenia were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related death occurred with carboplatin based treatment. Conclusion: This systemic analysis suggests that carboplatine based regimens are associated with a reasonable response rate and accepted toxicities for treating pediatric patients with Wilms tumors.

키워드

참고문헌

  1. Abu-Ghosh AM, Krailo MD, Goldman SC, et al (2002). Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol, 13, 460-9. https://doi.org/10.1093/annonc/mdf028
  2. Akkuzu G, Ayhan A (2013). Sexual functions of Turkish women with gynecologic cancer during the chemotherapy process. Asian Pac J Cancer Prev, 14, 3561-4. https://doi.org/10.7314/APJCP.2013.14.6.3561
  3. Anderson B, Krailo M, Davenport V et al (1999). Ifosfamide, carboplatin and etoposide (ICE) is a superb retrieval regimen in a large cohort (n = 107) of children with recurrent/refractory soft tissue sarcomas (STS): the Children's Cancer Group (CCG) experience. J Pediatr Hematol Oncol, 21, 337 (Abstr 505).
  4. Bag A, Pant NK, Jeena LM, et al (2013). GSTT1 null and MPO-463G>a polymorphisms and carboplatin toxicity in an Indian population. Asian Pac J Cancer Prev, 14, 4739-42. https://doi.org/10.7314/APJCP.2013.14.8.4739
  5. Butthongkomvong K, Sirachainan E, Jhankumpha S, et al (2013). Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev, 14, 3565-8. https://doi.org/10.7314/APJCP.2013.14.6.3565
  6. Cairo MS, Krailo M, Miser J et al (1996). Excellent results of the use of ifosfamide, carboplatin, etoposide (ICE) in children with recurrent or refractory solid tumors. Proc Am Soc Clin Oncol, 15, 468 (Abstr 1474).
  7. Cairo MS, Krailo MD, Weinthal JA et al (1998). A phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. Cancer, 83, 1449-60. https://doi.org/10.1002/(SICI)1097-0142(19981001)83:7<1449::AID-CNCR24>3.0.CO;2-3
  8. Cairo MS, Shen V, Krailo MD et al (2001). Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group Report. J Pediatr Hematol Oncol, 23, 30-8. https://doi.org/10.1097/00043426-200101000-00008
  9. Castello MA, Clerico A, Jenkner A, Dominici C. A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors (1990). Pediatr Hematol Oncol, 7, 129-35. https://doi.org/10.3109/08880019009033382
  10. Curtis BM, Williams DE, Broxmeyer HE et al (1991). Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA, 88, 5809-13. https://doi.org/10.1073/pnas.88.13.5809
  11. D'Angio GJ, Breslow N, Beckwith JB et al (1989). Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer, 64, 349-60. https://doi.org/10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q
  12. Daw N, Jones D, Gregornik D et al (1999). Renal function after ifosfamide, carboplatin and etoposide (ICE), nephrectomy, and radiation in children with high risk Wilms' tumor. Proc Am Soc Clin Oncol, 18, 560 (Abstr 2159).
  13. De Camargo B, Melaragno R, Saba e Silva N et al (1994). Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol, 22, 258-60. https://doi.org/10.1002/mpo.2950220409
  14. Ettinger LJ, Gaynon PS, Krailo MD et al (1994). A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children's Cancer Group. Cancer, 73, 1297-301. https://doi.org/10.1002/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#
  15. Frappaz D, Michon J, Hartmann O et al (1992). Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol, 10, 1592-601.
  16. Fu JH, Gao Z, Ren CC, et al (2013). Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer. Asian Pac J Cancer Prev, 14, 2377-81. https://doi.org/10.7314/APJCP.2013.14.4.2377
  17. Gentet JC, Doz F, Bouffet E et al (1994). Carboplatin and VP 16 in medulloblastoma: a Phase II Study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol, 23, 422-7. https://doi.org/10.1002/mpo.2950230506
  18. Green DM, Beckwith JB, Breslow NE et al (1994). Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol, 12, 2126-31.
  19. Green DM, Breslow NE, Evans I et al (1996). Treatment of children with stage IV favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol, 26, 147-52. https://doi.org/10.1002/(SICI)1096-911X(199603)26:3<147::AID-MPO1>3.0.CO;2-K
  20. Grundy P, Breslow N, Green DM et al (1989). Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol, 7, 638-47.
  21. Harrap KR (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev, 12, 21-33. https://doi.org/10.1016/0305-7372(85)90015-5
  22. Kalapurakal JA, Dome JS, Perlman EJ, et al (2004). Management of Wilms' tumour: current practice and future goals. Lancet Oncol, 5, 37-46. https://doi.org/10.1016/S1470-2045(03)01322-6
  23. Kaplan EL, Meier P (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
  24. Khemapech N, Oranratanaphan S, Termrungruanglert W, et al (2013). Salvage chemotherapy in recurrent platinumresistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox(R)). Asian Pac J Cancer Prev, 14, 2131-5. https://doi.org/10.7314/APJCP.2013.14.3.2131
  25. Kucukoztas N, Dizdar O, Rahatli S, et al (2013). Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey. Asian Pac J Cancer Prev, 14, 2959-62. https://doi.org/10.7314/APJCP.2013.14.5.2959
  26. Kung F, Hayes FA, Krischer J et al (1988). Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs, 6, 31-6.
  27. Kung FH, Bernstein ML, Camitta BM et al (1999). Ifosfamide/carboplatin/etoposide (ICE) in the treatment of advanced, recurrent Wilms' tumor. Proc Am Soc Clin Oncol, 18, 559 (Abstr 2156).
  28. Kung FH, Desai SJ, Dickerman JD et al (1995). Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group phase I/II study. J Pediatr Hematol Oncol, 17, 265-9. https://doi.org/10.1097/00043426-199508000-00009
  29. Kung FH, Pratt CB, Vega RA et al (1993). Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group phase II study. Cancer, 71, 1898-903. https://doi.org/10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q
  30. Lebwohl D, Canetta R (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer, 34, 1522-34. https://doi.org/10.1016/S0959-8049(98)00224-X
  31. Loehrer PJ Sr (1992). The history of ifosfamide. Semin Oncol, 19, 2-6.
  32. Marina NM, Poquette CA, Cain AM et al (2000). Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol, 22, 112-8. https://doi.org/10.1097/00043426-200003000-00007
  33. Marina NM, Rodman JH, Murry DJ et al (1994). Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst, 86, 544-8. https://doi.org/10.1093/jnci/86.7.544
  34. Marina NM, Wilimas JA, Meyer WH et al (1994). Refining therapeutic strategies for patients with resistant Wilms' tumor. Am J Pediatr Hematol Oncol, 16, 296-300.
  35. Miser J, Krailo M, Hammond GD (1993). The combination of ifosfamide (IFOS), etoposide (VP16), and mesna (M): a very active regimen in the treatment of recurrent Wilms' tumor (WT). Proc Am Soc Clin Oncol, 12, 417 (Abstr 1432).
  36. Miser JS, Kinsella TJ, Triche TJ et al (1987). Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol, 5, 1191-8.
  37. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
  38. O'Dwyer PJ, Leyland-Jones B, Alonso MT et al (1985). Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med, 312, 692-700. https://doi.org/10.1056/NEJM198503143121106
  39. Oranratanaphan S, Khemapech N (2013). Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. Asian Pac J Cancer Prev, 14, 4693-7. https://doi.org/10.7314/APJCP.2013.14.8.4693
  40. Ozdemir O, Ozdemir P, Veral A, et al (2013). ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev, 14, 4679-83. https://doi.org/10.7314/APJCP.2013.14.8.4679
  41. Pappo AS, Etcubanas E, Santana VM et al (1993). A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer, 71, 2119-25. https://doi.org/10.1002/1097-0142(19930315)71:6<2119::AID-CNCR2820710629>3.0.CO;2-Y
  42. Pein F, Michon J, Valteau-Couanet D et al (1998). Highdose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol, 16, 3295-301. Abstract
  43. Pein F, Pinkerton R, Tournade MF et al (1993). Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol, 11, 1478-81.
  44. Pein F, Rey A, de Kraker J et al (1999). Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms' tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med Pediatr Oncol, 33, 170 (Abstr 0111).
  45. Pein F, Tournade MF, Zucker JM et al (1994). Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-a phase II study by the French Society of Pediatric Oncology. J Clin Oncol, 12, 931-36.
  46. Pinkerton CR, Rogers H, James C et al (1985) . A phase II study of ifosfamide in children with recurrent solid tumours. Cancer Chemother Pharmacol, 15, 258-62.
  47. Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, et al (2013). Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev, 14, 2421-7. https://doi.org/10.7314/APJCP.2013.14.4.2421
  48. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, et al (2003).: Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol, 21, 3269-75. https://doi.org/10.1200/JCO.2003.01.062
  49. Rose WC, Schurig JE (1985). Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev, 12, 1-19.
  50. Shen V, Morris E, Davenport V et al (1999). Ifosfamide, carboplatin and etoposide (ICE) is an excellent retrieval regimen in childen with recurrent/refractory CNS malignancies: the Children's Cancer Group (CCG) experience. Proc Am Soc Clin Oncol, 18, 558 (Abstr 2151).
  51. Tannous R, Giller R, Holmes E et al (2000). Intensive therapy for high risk (HR) relapsed Wilms' tumor (WT). A CCG-4921/POG-9445 study report. Proc Am Soc Clin Oncol, 19, 2315 (Abstr 2315).
  52. Tournade MF, Lemerle J, Brunat-Mentigny M et al (1988). Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol, 6, 793-96.
  53. Zhang YY, Gu KS (2013). DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer. Asian Pac J Cancer Prev, 14, 5507-12. https://doi.org/10.7314/APJCP.2013.14.9.5507

피인용 문헌

  1. Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer vol.96, pp.2, 2017, https://doi.org/10.1097/MD.0000000000005797